Articles with public access mandates - Karen AutioLearn more
Not available anywhere: 1
MP24-01
AT Lenis, V Ravichandran, H Truong, P Reisz, B Nweji, K Autio, M Morris, ...
Mandates: Fonds de recherche du Québec - Santé
Available somewhere: 28
Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade
W Abida, ML Cheng, J Armenia, S Middha, KA Autio, HA Vargas, ...
JAMA oncology 5 (4), 471-478, 2019
Mandates: US Department of Defense, US National Institutes of Health
High-risk prostate cancer—classification and therapy
AJ Chang, KA Autio, M Roach III, HI Scher
Nature reviews Clinical oncology 11 (6), 308-323, 2014
Mandates: US National Institutes of Health
Safety, antitumor activity, and immune activation of pegylated recombinant human interleukin-10 (AM0010) in patients with advanced solid tumors
A Naing, KP Papadopoulos, KA Autio, PA Ott, MR Patel, DJ Wong, ...
Journal of Clinical Oncology 34 (29), 3562-3569, 2016
Mandates: US National Institutes of Health
PEGylated IL-10 (Pegilodecakin) induces systemic immune activation, CD8+ T cell invigoration and polyclonal T cell expansion in cancer patients
A Naing, JR Infante, KP Papadopoulos, IH Chan, C Shen, NP Ratti, ...
Cancer Cell 34 (5), 775-791. e3, 2018
Mandates: US National Institutes of Health
Safety and efficacy of BIND-014, a docetaxel nanoparticle targeting prostate-specific membrane antigen for patients with metastatic castration-resistant prostate cancer: a …
KA Autio, R Dreicer, J Anderson, JA Garcia, A Alva, LL Hart, MI Milowsky, ...
JAMA oncology 4 (10), 1344-1351, 2018
Mandates: US National Institutes of Health
Probody therapeutics: an emerging class of therapies designed to enhance on-target effects with reduced off-tumor toxicity for use in immuno-oncology
KA Autio, V Boni, RW Humphrey, A Naing
Clinical Cancer Research 26 (5), 984-989, 2020
Mandates: US National Institutes of Health
Targeting the androgen receptor in prostate and breast cancer: several new agents in development
T Proverbs-Singh, JL Feldman, MJ Morris, KA Autio, TA Traina
Endocrine-related cancer 22 (3), R87-R106, 2015
Mandates: US National Institutes of Health
Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial
A Naing, DJ Wong, JR Infante, WM Korn, R Aljumaily, KP Papadopoulos, ...
The Lancet Oncology 20 (11), 1544-1555, 2019
Mandates: US National Institutes of Health
Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort
E Basch, KA Autio, MR Smith, AV Bennett, AL Weitzman, C Scheffold, ...
European urology 67 (2), 310-318, 2015
Mandates: US National Institutes of Health
Therapeutic strategies for bone metastases and their clinical sequelae in prostate cancer
KA Autio, HI Scher, MJ Morris
Current treatment options in oncology 13, 174-188, 2012
Mandates: US National Institutes of Health
Immunomodulatory activity of a colony-stimulating factor-1 receptor inhibitor in patients with advanced refractory breast or prostate cancer: a phase I study
KA Autio, CA Klebanoff, D Schaer, JSW Kauh, SF Slovin, M Adamow, ...
Clinical Cancer Research 26 (21), 5609-5620, 2020
Mandates: US National Institutes of Health
Phase I study of MK-4166, an anti-human glucocorticoid-induced TNF receptor antibody, alone or with pembrolizumab in advanced solid tumors
KP Papadopoulos, K Autio, T Golan, K Dobrenkov, E Chartash, Q Chen, ...
Clinical Cancer Research 27 (7), 1904-1911, 2021
Mandates: US National Institutes of Health
Prevalence of pain and analgesic use in men with metastatic prostate cancer using a patient-reported outcome measure
KA Autio, AV Bennett, X Jia, M Fruscione, TM Beer, DJ George, ...
Journal of oncology practice 9 (5), 223-229, 2013
Mandates: US National Institutes of Health
Differences in prostate cancer genomes by self-reported race: contributions of genetic ancestry, modifiable cancer risk factors, and clinical factors
KH Stopsack, S Nandakumar, K Arora, B Nguyen, SE Vasselman, B Nweji, ...
Clinical Cancer Research 28 (2), 318-326, 2022
Mandates: US Department of Defense, US National Institutes of Health
Severe hypocalcemia associated with denosumab in metastatic castration-resistant prostate cancer: risk factors and precautions for treating physicians
KA Autio, A Farooki, IG Glezerman, A Chan, CW Schneider, HC Barr, ...
Clinical Genitourinary Cancer 13 (4), e305-e309, 2015
Mandates: US National Institutes of Health
CX-072 (pacmilimab), a Probody® PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study
A Naing, F Thistlethwaite, EGE De Vries, FALM Eskens, N Uboha, PA Ott, ...
Journal for immunotherapy of cancer 9 (7), 2021
Mandates: US National Institutes of Health
Repetitively dosed docetaxel and 153samarium‐EDTMP as an antitumor strategy for metastatic castration‐resistant prostate cancer
KA Autio, N Pandit‐Taskar, JA Carrasquillo, RD Stephenson, SF Slovin, ...
Cancer 119 (17), 3186-3194, 2013
Mandates: US National Institutes of Health
CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study
RE Sanborn, O Hamid, EGE De Vries, PA Ott, J Garcia-Corbacho, V Boni, ...
Journal for immunotherapy of cancer 9 (7), 2021
Mandates: US National Institutes of Health
Targeting bone physiology for the treatment of metastatic prostate cancer
KA Autio, MJ Morris
Clinical advances in hematology & oncology: H&O 11 (3), 134, 2013
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program